Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study

Fig. 1

Alteration of serum uric acid level due to febuxostat therapy. The changes in serum uric acid (UA) levels after febuxostat administration (baseline, 3 and 6 months after treatment initiation). a All patients (n = 178), b antihyperuricemic naïve (n = 118) vs. antihyperuricemic switched groups (n = 60), c eGFR <30 (n = 75) vs. eGFR ≥30 ml/min/1.73 m2 groups (n = 103), d urine protein level < 0.5 (n = 81) vs. urine protein level ≥ 0.5 g/gCre groups (n = 92). The UA levels represent the mean ± SD. **p < 0.01, compared with baseline UA level in each group (Wilcoxon signed-rank test)

Back to article page
\